search button
Open Access

Puerarin inhibits bladder cancer cell proliferation through the mTOR/p70S6K signaling pathway

  • Authors:
    • Kehua Jiang
    • Hongbo Chen
    • Kun Tang
    • Wei Guan
    • Hui Zhou
    • Xiaolin Guo
    • Zhiqiang Chen
    • Zhangqun Ye
    • Hua Xu

  • View Affiliations

  • Published online on: October 31, 2017     https://doi.org/10.3892/ol.2017.7298
  • Pages: 167-174

  • Copyright: © Jiang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Puerarin, as a novel oncotherapeutic agent, may exert anticancer effects and inhibit the proliferation of cancer cells. To explore the effects of puerarin on human bladder cancer cells, and to elucidate the potential mechanism underlying these effects, a Cell Counting Kit‑8 assay was used to examine the proliferation of T24 and EJ cells following puerarin treatment. The effects of puerarin treatment on the cell cycle were detected by flow cytometry (FCM), while puerarin-induced cell apoptosis was detected by terminal deoxynucleotidyl transferase dUTP nick end labeling and FCM, and the cellular ultrastructural morphological changes were observed by transmission electron microscopy. Cell invasion was examined using a Transwell assay with Matrigel. The expression levels of mechanistic target of rapamycin (mTOR), phosphorylated (p)‑mTOR, p70‑S6 kinase (p70S6K) and p‑p70S6K proteins in the mTOR signaling pathway were then assessed by western blotting. The results demonstrated that puerarin may inhibit bladder cancer cell viability, block the cell cycle in the G0/G1 phase and induce apoptosis in bladder cancer cells. The expression levels of p‑mTOR and p‑p70S6K proteins were downregulated, while no change was observed in the expression levels of mTOR and p70S6K proteins when T‑24 and EJ cells were treated by puerarin. In the present study, puerarin was demonstrated to inhibit the viability of human bladder cancer cells. These effects may be due to the puerarin‑induced downregulation of proteins in the mTOR/p70S6K signaling pathway, and the present study may provide the experimental basis for puerarin to be considered as a promising novel anti‑tumor drug for the treatment of bladder cancer.
View Figures
View References

Related Articles

Journal Cover

January-2018
Volume 15 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.5
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 5.7
  • CiteScore Rank: Q2: #139/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.574
  • SCImago Journal Rank (SJR): 0.644
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Jiang K, Chen H, Tang K, Guan W, Zhou H, Guo X, Chen Z, Ye Z and Xu H: Puerarin inhibits bladder cancer cell proliferation through the mTOR/p70S6K signaling pathway. Oncol Lett 15: 167-174, 2018.
APA
Jiang, K., Chen, H., Tang, K., Guan, W., Zhou, H., Guo, X. ... Xu, H. (2018). Puerarin inhibits bladder cancer cell proliferation through the mTOR/p70S6K signaling pathway. Oncology Letters, 15, 167-174. https://doi.org/10.3892/ol.2017.7298
MLA
Jiang, K., Chen, H., Tang, K., Guan, W., Zhou, H., Guo, X., Chen, Z., Ye, Z., Xu, H."Puerarin inhibits bladder cancer cell proliferation through the mTOR/p70S6K signaling pathway". Oncology Letters 15.1 (2018): 167-174.
Chicago
Jiang, K., Chen, H., Tang, K., Guan, W., Zhou, H., Guo, X., Chen, Z., Ye, Z., Xu, H."Puerarin inhibits bladder cancer cell proliferation through the mTOR/p70S6K signaling pathway". Oncology Letters 15, no. 1 (2018): 167-174. https://doi.org/10.3892/ol.2017.7298